Disease/Infection News

RSS

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Current myths vs. realities in global AIDS funding

Activists at the International AIDS Conference in Vienna are charging developed and developing country governments with writing checques that bounce to the millions of people in need of lifesaving HIV treatment. Despite the gains in treatment numbers reported by WHO, the International Treatment Preparedness Coalition's (ITPC), latest report, Rationing Funds, Risking Lives, documents early warnings of the global pullback on AIDS commitment and funding.

22 Jul 2010

Study marks significant milestone for microbicide research field, HIV prevention

Today we congratulate the Centre for the AIDS Programme of Research in South Africa and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

22 Jul 2010

Flat global funding for HIV prevention research could have serious consequences: Report

Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward.

22 Jul 2010

Experts outline three elements necessary for ending HIV/AIDS pandemic

According to a new editorial, the world can control and ultimately end the HIV/AIDS pandemic through a three-pronged strategy

22 Jul 2010

AIDS 2010: Advocates march in Vienna for human rights of HIV/AIDS patients

Thousands of HIV/AIDS advocates, gathered for the International AIDS Conference-AIDS 2010, "marched through Vienna's city centre on Tuesday evening, demanding more respect for human rights in the fight against HIV," Agence France-Presse reports.

22 Jul 2010

AIDS 2010 interviews

Managing editor of the Kaiser Daily Global Health Policy Report, Jill Braden Balderas, interviews global health leaders participating in AIDS 2010.

22 Jul 2010

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

"In parts of Africa, only about half of babies born to mothers with HIV receive the HIV prevention drug nevirapine," according to a study published Wednesday, HealthDay News/U.S. News & World Report reports.

22 Jul 2010

AIDS 2010 opinions: U.S. AIDS funding; Human rights and HIV; Invest in primary care; Microbicide gel's possibilities

"Having met President [Barack] Obama, I'm confident that he's a man of conscience who shares my commitment to bringing hope and care to the world's poor. But I am saddened by his decision to spend less than he promised to treat AIDS patients in Africa," Desmond Tutu, archbishop emeritus of Cape Town and honorary chairman of the Global AIDS Alliance, writes in a New York Times opinion piece.

22 Jul 2010

CFAR receives a five-year renewal grant to continue AIDS research

The Case Western Reserve University/University Hospitals Case Medical Center Center for AIDS Research announced today it has received a five-year renewal grant from the National Institutes of Health for $9 million. The CFAR provides clinical and technological support to researchers working on HIV-related projects at Case Western Reserve, University Hospital Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, and several international sites.

22 Jul 2010

Today's OpEds: U.S. and AIDS; Mass. example on health reform?; Unions and health costs

George W. Bush made an impressive commitment to the international fight against AIDS when he formed the President's Emergency Plan for AIDS Relief program. … Thanks to these efforts — and similar initiatives ... the number of African patients with access to AIDS drugs jumped tenfold from 2003 to 2008. Since 2004, the AIDS-related mortality rate in sub-Saharan Africa has dropped 18 percent. Yet President Obama added only $366 million to the program this year — well below the $1 billion per year he promised to add when he was on the campaign trail (Desmond Tutu, 7/20).

22 Jul 2010

NIH awards KGI $3.6M grant to develop diagnostic assays and devices for multi-drug resistant tuberculosis

Keck Graduate Institute (KGI) Director of Research Angelika Niemz has been awarded a four-year, $3.6 million collaborative research grant from the National Institutes of Health (NIH).

21 Jul 2010

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Most older gay and bisexual men enrolled in a long-term study of HIV used recreational drugs infrequently over a 10-year period, report University of Pittsburgh Graduate School of Public Health researchers at the XVIII International AIDS Conference.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

The call for human rights as a fundamental component of efforts to prevent new infections and provide treatment for people living with HIV pervaded the XVIII International AIDS Conference today as delegates and local residents prepared for the HIV and Human Rights March through the streets of Vienna this evening. Conference participants are giving voice to the conference theme of Rights Here, Right Now through a number of plenary presentations, sessions, and Global Village and Youth Programme activities.

21 Jul 2010

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

This week, the National Advisory Committee on Immunization updated and strengthened its statement related to the use of rotavirus vaccines in Canada. Rotavirus infection is the most common cause of severe gastroenteritis in children under the age of three. The NACI statement now includes Grade A recommendations (good evidence to recommend immunization) for healthy and preterm infants.

21 Jul 2010

AMP particpates at FDA's public meeting on oversight of laboratory developed tests

The Association for Molecular Pathology participated in the Food and Drug Administration Center for Devices and Radiological Health public meeting on the oversight of laboratory developed tests. Dr. Karen Mann, President of AMP, served on the second panel of the meeting titled, Clinical Laboratory Challenges. Additionally, Dr. Elaine Lyon, Chair of the AMP Professional Relations Committee, presented public comments. "AMP believes that LDTs are an essential and central component of medical practice," said Dr. Lyon, "Without LDTs, the practice of medicine that we know today would be severely reduced in scope."

21 Jul 2010

Disease/Infection News

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Current myths vs. realities in global AIDS funding

Study marks significant milestone for microbicide research field, HIV prevention

Flat global funding for HIV prevention research could have serious consequences: Report

Experts outline three elements necessary for ending HIV/AIDS pandemic

AIDS 2010: Advocates march in Vienna for human rights of HIV/AIDS patients

AIDS 2010 interviews

AIDS 2010 studies, releases: PMTCT, treating children, male circumcision; National prevention programs; IDUs

AIDS 2010 opinions: U.S. AIDS funding; Human rights and HIV; Invest in primary care; Microbicide gel's possibilities

CFAR receives a five-year renewal grant to continue AIDS research

Today's OpEds: U.S. and AIDS; Mass. example on health reform?; Unions and health costs

NIH awards KGI $3.6M grant to develop diagnostic assays and devices for multi-drug resistant tuberculosis

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

New insights on early pathogenic events, strategies for preventing HIV infection

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Health Canada grants Osiris Priority Review for Prochymal NDS

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

NACI updates, strengthens statement related to the use of rotavirus vaccines in Canada

AMP particpates at FDA's public meeting on oversight of laboratory developed tests

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Latest News